2024-12-14 - Analysis Report
## Teladoc Health Inc (TDOC) Stock Review

**1. Performance Comparison and Divergence:**

Teladoc Health (TDOC) significantly underperformed the S&P 500 (VOO) over the given period.  The cumulative return for TDOC is -63.78%, while VOO shows a 120.86% return. This represents a substantial divergence of -184.6%, placing it at the 4th percentile of historical relative performance compared to the S&P 500.  Teladoc's performance has been far below the benchmark index.

**Company Overview:** Teladoc Health Inc. is a telehealth company providing virtual healthcare services.


**Alpha/Beta Analysis:** The provided alpha values consistently show 0.0 indicating no alpha generation relative to the benchmark.  Beta values vary significantly over time, reflecting high volatility and sensitivity to market movements. High CAGR values in earlier periods are counterbalanced by extreme negative CAGR in recent years, reflecting the company's struggles.  MDD (Maximum Drawdown) values are substantial and represent significant losses from peak to trough.

**2. Recent Price Movement:**

* **Closing Price:** $10.42
* **5-Day Moving Average:** $10.498
* **20-Day Moving Average:** $10.588
* **60-Day Moving Average:** $9.5717

The price is currently below its 5 and 20-day moving averages, indicating a short-term bearish trend. However, it is above the 60-day moving average suggesting some potential support.

**3. Technical Indicators and Expected Return:**

* **RSI (48.08):**  Indicates the stock is neither overbought nor oversold, suggesting a neutral sentiment.
* **PPO (-1.38):** A negative PPO suggests bearish momentum.
* **Relative Divergence:**  A recent 0.0 change in relative divergence indicates recent short-term downward pressure.
* **Expected Return (0.0%):**  The expected return is 0.0%, indicating no projected alpha generation relative to the S&P 500 over the long term (2+ years) based on current data.  This aligns with the consistent alpha of 0.0 shown in the longer-term analysis.  No significant price jumps (rapid increase or decline) are evident in the provided data.


**4. Recent Earnings Analysis:**

The recent quarterly earnings show a consistent trend of negative EPS and relatively flat revenues.  There's no information about whether these figures beat or missed expectations; however, the negative EPS is noteworthy.

* **Revenue:** Revenue is relatively stable around $0.64 - $0.66 billion across the quarters, showing minimal growth.
* **EPS:**  EPS has consistently been negative, with significant swings in magnitude, indicating operational challenges. There is no clear trend in revenue.


**5. Financial Information Analysis:**

* **Revenue and Profitability:** Revenue remains relatively stable but the high profit margins reported might be misleading in the absence of detailed information about the calculation methodology. Further analysis of costs and expenses is needed for a complete understanding of profitability.
* **Capital and Profitability:**  ROE is consistently negative, indicating the company is not generating returns on its equity.  Significant fluctuations in Equity values raise concerns about the financial stability of the company.

**6. News and Recent Issues:**

This section requires information on recent news releases, market outlook, and analyst opinions to complete the analysis. The provided data lacks this crucial context.

**7.  Overall Analysis:**

Teladoc Health shows a deeply concerning picture.  Significant underperformance against the S&P 500, consistently negative EPS, unstable ROE, and minimal revenue growth paint a bearish outlook. While the RSI and moving average indicators do not show extreme bearish signals, the negative PPO and long-term negative CAGR strongly suggest caution.  Without news and analyst insights, a comprehensive conclusion is difficult, but the current financial picture is alarming.  Further investigation into the reasons behind the negative EPS, the consistency of high profit margins despite negative ROE, and recent news is crucial before any investment decision.

**8. Disclaimer:** This analysis is based solely on the provided data and does not constitute financial advice.  Independent research and consultation with a financial advisor are strongly recommended before making any investment decisions.  The lack of certain data points (especially news and analyst opinions) limits the comprehensiveness of this analysis.
